Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Antimicrob Agents Chemother ; 53(5): 1998-2004, 2009 May.
Article in English | MEDLINE | ID: mdl-19258268

ABSTRACT

Carbapenem-resistant Klebsiella strains carrying Klebsiella pneumoniae carbapenemases (KPC) are endemic to New York City and are spreading across the United States and internationally. Recent studies have indicated that the KPC structural gene is located on a 10-kb plasmid-borne element designated Tn4401. Fourteen Klebsiella pneumoniae strains and one Klebsiella oxytoca strain isolated at a New York City hospital in 2005 carrying either bla(KPC-2) or bla(KPC-3) were examined for isoforms of Tn4401. Ten of the Klebsiella strains contained a 100-bp deletion in Tn4401, corresponding to the Tn4401a isoform. The presence of this deletion adjacent to the upstream promoter region of bla(KPC) in Tn4401a resulted in a different -35 promoter sequence of TGGAGA than that of CTGATT present in isoform Tn4401b. Complete sequencing of one plasmid carrying bla(KPC) from each of three nonclonal isolates indicated the presence of genes encoding other types of antibiotic resistance determinants. The 70.6-kb plasmid from K. pneumoniae strain S9 carrying bla(KPC-2) revealed two identical copies of Tn4401b inserted in an inverse fashion, but in this case, one of the elements disrupted a group II self-splicing intron. In K. pneumoniae strain S15, the Tn4401a element carrying bla(KPC-2) was found on both a large 120-kb plasmid and a smaller 24-kb plasmid. Pulsed-field gel electrophoresis results indicate that the isolates studied represent a heterogeneous group composed of unrelated as well as closely related Klebsiella strains. Our results suggest that endemic KPC-positive Klebsiella strains constitute a generally nonclonal population comprised of various alleles of bla(KPC) on several distinct plasmid genetic backgrounds. This study increases our understanding of the genetic composition of the evolving and expanding role of KPC-producing, healthcare-associated, gram-negative pathogens.


Subject(s)
Bacterial Proteins/genetics , DNA Transposable Elements , Drug Resistance, Bacterial , Klebsiella oxytoca , Klebsiella pneumoniae , Plasmids/genetics , Transposases/genetics , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/metabolism , Carbapenems/pharmacology , Hospitals, Urban , Humans , Isoenzymes/genetics , Klebsiella Infections/epidemiology , Klebsiella Infections/microbiology , Klebsiella oxytoca/drug effects , Klebsiella oxytoca/enzymology , Klebsiella oxytoca/genetics , Klebsiella oxytoca/isolation & purification , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Microbial Sensitivity Tests , New York City/epidemiology , Transposases/metabolism , beta-Lactamases/metabolism
2.
Drug Dev Ind Pharm ; 28(2): 177-91, 2002.
Article in English | MEDLINE | ID: mdl-11926362

ABSTRACT

In this paper, we describe an assay using radioactive rubidium (86Rb) efflux to screen functional human ether-a go-go-related gene (HERG) K+ channels in a high-throughput screening (HTS) format. This assay offers an alternative way to examine junctional interactions between chemical compounds and HERG K+ channels. Follow-up experiments and discussions were carried out to address a variety of factors that affect potency evaluation within the Rb efflux assay. Factors that can affect the assay results, such as assay time, efflux rate, and compound blocking kinetics, are discussed in detail. Our results provide some explanations for the variances of the assay results and offer some guidelines for using the Rb efflux assay to evaluate compound interactions with HERG K+ channels in the pharmaceutical industry.


Subject(s)
Cation Transport Proteins , Potassium Channels, Voltage-Gated , Potassium Channels/drug effects , Rubidium Radioisotopes , Biological Assay/methods , Cloning, Molecular , DNA, Complementary , Drug Evaluation, Preclinical , Drug Industry , Ether-A-Go-Go Potassium Channels , Guidelines as Topic , Kinetics , Potassium Channels/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL